So, when stating that Sunrise failed in low b2pg1 patients, it is just as possible that Bavi was overdosed.
Whether dosing was "the" issue, or you are right and they should have switched to the BB based tech (nicked or not), the failure to understand this issue in early stage trials is simply pathetic.
Not only elephants, but a blind man not seeing the elephants.
Excellent post exwannabe. I do have one correction. It should be a blind man not feeling, hearing or smelling the elephant in the room despite those the noise, bulk and odor emanating from it. I am truly stunned that anyone could think that PPHM management has been doing a good job or has merely been the victim of totally unexpected road hazards.